Boehringer to launch biosimilars unit

Boehringer Ingelheim last week said it is launching a business unit for developing and commercializing its own biosimilar products. By having this dedicated in-house focus, B-I will likely enhance its contract manufacturing arm with additional capabilities over time.

As evidence of its biotech expertise, the German company has already launched 19 DNA-derived biopharmaceutical products, according to Frost & Sullivan. That's one of the reasons the market-watcher recently bestowed the 2011 Frost & Sullivan Europe Competitive Strategy Leadership Award in Bio Pharmaceutical Contract Manufacturing to the drugmaker.

"The biggest competitive assets of B-I include its strong R&D portfolio with a well-defined in-house biologics pipeline," says research analyst Aiswariya Chidambaram, via email. That pipeline spans "key therapeutic areas and the proprietary technologies for the development of high-titer processes and high-throughput screening methods in mammalian and microbial contract manufacturing."

Among B-I's biopharma credits are inflammatory-disease treatment Enbrel, for Amgen and Pfizer/Wyeth; respiratory infection drug Synagis, for MedImmune; multiple sclerosis treatment Betaferon/Betaseron, for Bayer Health Care; and cancer treatment Erbitux, for Merck Serono.

- see the Boehringer biosimilars release
- here's the Frost & Sullivan award announcement

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.